OneMedNet director buys 142,857 shares for $90K

OneMedNet’s Chief Medical Officer made a $90,000 direct equity investment via a VWAP-priced subscription agreement, increasing his reported direct holdings.

Rhea-AI Filing Summary

OneMedNet Corp (ONMD) reported that Jeffrey Yu, a director, Chief Medical Officer and more-than-10% owner, entered into a subscription agreement to purchase 142,857 shares of common stock on September 10, 2026 for a $90,000 investment, valued at a $0.63 volume-weighted average price over the prior 10 trading days. Following this transaction, he holds 8,923,267 shares directly and an additional 1,311,970 shares are held indirectly in a trust for his children with an independent trustee; he disclaims beneficial ownership of the trust shares. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 142,857 shares

Net Buy 2 txns

Insider Yu Jeffrey

Role Chief Medical Officer

Bought 142,857 shs ($90K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	142,857	$0.63	$90K
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 8,923,267 shares (Direct); Common Stock — 1,311,970 shares (Indirect, By trust for children)

Footnotes (3)

1. F1. On September 10, 2026, the issuer entered into a subscription agreement with the reporting person for a $90,000 investment in the issuer.
2. F2. The shares were valued at the volume-weighted average price (VWAP) of the issuer for the 10 trading days immediately prior to the purchase date.
3. F3. The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.

Key Figures

Shares purchased: 142,857 shares Investment amount: $90,000 VWAP-based share value: $0.63 per share +2 more

5 metrics

Shares purchased 142,857 shares Common stock acquired by Jeffrey Yu on September 10, 2026

Investment amount $90,000 Subscription agreement between OneMedNet Corp and Jeffrey Yu

VWAP-based share value $0.63 per share Volume-weighted average price over 10 trading days before purchase

Direct holdings after transaction 8,923,267 shares Jeffrey Yu’s directly owned OneMedNet common stock following purchase

Indirect trust holdings 1,311,970 shares Shares held by trust for children; beneficial ownership disclaimed

Key Terms

subscription agreement, volume-weighted average price (VWAP), independent trustee, beneficial ownership

4 terms

subscription agreement financial

"entered into a subscription agreement with the reporting person for a $90,000 investment"

A subscription agreement is a legal contract in which an investor agrees to buy a specific number of a company’s shares or other securities under set terms, including price, payment method and conditions for closing the sale. It matters to investors because it legally locks in their purchase and the company’s obligations, determines ownership percentage and any investor rights, and can include conditions or promises that affect future control or returns—like signing a detailed purchase order for equity.

volume-weighted average price (VWAP) financial

"valued at the volume-weighted average price (VWAP) of the issuer"

Volume-weighted average price (VWAP) is the average price of a security over a trading period where each trade’s price is weighted by how many shares were traded, so larger trades pull the average more than tiny ones. Investors and traders use VWAP as a benchmark to judge whether a trade was executed at a favorable price—similar to checking whether you paid more or less than the typical price when most people were buying or selling.

independent trustee financial

"shares are held by trust with an independent trustee, in which the reporting person"

beneficial ownership financial

"The reporting person disclaims beneficial ownership of these shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider purchase did ONMD report for Jeffrey Yu on September 10, 2026?

Jeffrey Yu entered into a subscription agreement to purchase 142,857 ONMD common shares on September 10, 2026, representing a $90,000 investment valued at a $0.63 volume-weighted average price over the 10 trading days before the purchase date.

What price per share did Jeffrey Yu effectively pay for ONMD stock in this Form 4?

The 142,857 ONMD shares were valued at a $0.63 volume-weighted average price (VWAP), based on the issuer’s VWAP over the 10 trading days immediately prior to the September 10, 2026 purchase date.

How many ONMD shares does Jeffrey Yu hold directly after this reported transaction?

After the reported purchase, Jeffrey Yu holds 8,923,267 ONMD common shares directly. This figure reflects his direct ownership position following the September 10, 2026 subscription agreement investment.

What indirect ONMD holdings related to Jeffrey Yu are disclosed in this Form 4?

An additional 1,311,970 ONMD shares are held indirectly in a trust for Jeffrey Yu’s children with an independent trustee. The filing states he has no investment control and disclaims beneficial ownership of these shares.

Was Jeffrey Yu’s ONMD stock purchase made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmed and there is no footnote indicating a pre-arranged trading plan, so no Rule 10b5-1 plan is reported for this transaction.

What type of agreement governed Jeffrey Yu’s ONMD stock investment?

The investment was made under a subscription agreement between OneMedNet Corp and Jeffrey Yu for a $90,000 investment in the issuer, dated September 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 08:47 PM Accepted by SEC EDGAR 09/14/2026 - 08:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jeffrey

(Last) (First) (Middle)

6385 OLD SHADY OAK ROAD,

SUITE 250

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OneMedNet Corp [ ONMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		P(1)		142,857	A	$0.63(2)	8,923,267	D
Common Stock								1,311,970	I	By trust for children(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 10, 2026, the issuer entered into a subscription agreement with the reporting person for a $90,000 investment in the issuer.

2. The shares were valued at the volume-weighted average price (VWAP) of the issuer for the 10 trading days immediately prior to the purchase date.

3. The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.

	/s/ Robert Golden, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)